Phase I trial of cancer vaccine with multiple peptides derived from novel onco-antigen and anti-angiogenic antigens for patients with advanced non-small cell lung cancer (NSCLC).

Hiroyuki Suzuki,Takeo Hasegawa,Jun Ohsugi,Mika Hoshino,Mitsunori Higuchi,Yutaka Shio,Koji Yoshida,Takuya Tsunoda,Yusuke Nakamura,Mitsukazu Gotoh

Phase I trial of cancer vaccine with multiple peptides derived from novel onco-antigen and anti-angiogenic antigens for patients with advanced non-small cell lung cancer (NSCLC).

2017

Hiroyuki Suzuki
Takeo Hasegawa
Jun Ohsugi
Mika Hoshino
Mitsunori Higuchi
Yutaka Shio
Koji Yoshida
Takuya Tsunoda
Yusuke Nakamura
Mitsukazu Gotoh

e13015 Background: Two phase I clinical trials were conducted on patients with advanced or recurrent NSCLC to evaluate the safety, immunogenicity and clinical response of a multiple peptide vaccine...

Keywords:

Pathology
Peptide vaccine
Clinical trial
non-small cell lung cancer (NSCLC)
Antigen
Internal medicine
Oncology
Immunogenicity
Medicine
Cancer vaccine
Recurrent NSCLC
anti angiogenic
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations